Literature DB >> 31248367

Acute myocardial infarction and transient elevated anticardiolipin antibody in a young adult with possible familial hypercholesterolemia: a case report : Anticardiolipin antibody and myocardial infarction.

Xin Su1,2, Aqian Wang1,2, Hai Zhu1, Hongling Su1, Yichao Duan1,3, Shanlian Wu2, Min Zhang4, Yan Huang1, Xing Zhou5, Yunshan Cao6.   

Abstract

BACKGROUND: Familial hypercholesterolemia (FH) can lead to premature coronary heart disease. Anticardiolipin antibody may be a contributor for thrombosis. Here, we report an adult with possible FH suffered from premature myocardial infarction that may be triggered by transient increased anticardiolipin antibody. CASE
PRESENTATION: A 29-year-old male had presented with a history of 2-h chest pain and numbness of left upper arm before 5 days. The electrocardiogram (ECG) had demonstrated inferior wall myocardial infarction (MI). Five days later he was admitted to our hospital and diagnosed as acute MI and possible FH (premature coronary heart disease, low density lipoprotein cholesterol of 5.90 mmol/L) with increased anticardiolipin antibody (up to 120 RU/ml). Other auto-antibodies including β2-glicoprotein antibodies IgM, IgA, IgG, lupus anticoagulant (LA), antinuclear antibodies, anti-myocardial antibody were normal. Coronary artery angiography (CAG) showed right coronary artery was total occlusion from the middle segment. Then he underwent percutaneous coronary intervention with a stent. Four days later, he was discharged with complete recovery. CAG showed intra-stent restenosis and anticardiolipin antibody level was normal and the patient had no any symptoms at 6-month follow-up.
CONCLUSIONS: Transient elevated anticardiolipin antibody may be a trigger or biomarker of cardiac thrombotic events in younger atherosclerotic patients.

Entities:  

Keywords:  Anticardiolipin antibody; Familial hypercholesterolemia; Myocardial infarction; Thrombosis

Year:  2019        PMID: 31248367      PMCID: PMC6598355          DOI: 10.1186/s12872-019-1135-y

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


Background

It is well known that the incidence of premature cardiovascular disease (CVD) is low. Previous studies have revealed that patients aged less than 40 years old only account for 1.2% of all patients with MI [1, 2]. Numerous studies have reported that multiple risk factors relate to ST segment elevated MI (STEMI) including male, smoking state, family history of CVD, dyslipidemia, hypertension, and diabetes mellitus (DM) in patients aged < 40 years [3-7]. Familial hypercholesterolemia (FH) as a type of dyslipidemia is one of the most common risk factors in patients with premature atherosclerotic cardiovascular disease (ASCVD) [8, 9]. In addition, previous evidence has proved that the presence of antiphospholipid antibodies (aPL) increases the thrombotic risk and the decreased titers or the disappearance of aPL closely relates to better prognosis [10-13]. Thus, a transient increase of anticardiolipin antibody induced by bacteria or viruses infection may contribute to the risk of thrombosis in patient with possible FH [14, 15].

Case presentation

A 29-year-old male patient had presented with a history of 2-h chest pain and numbness of left upper arm before 5 days. The electrocardiogram (ECG) indicated acute inferior wall myocardial infarction (MI) and he refused any treatment at that time. Five days later he was admitted to our hospital for further examination. Physical examination showed no abnormal including arcus corneae and xanthelasma in eyelid, extensor tendon and achilles tendons. He had no histories of diabetes mellitus, hyperthyroidism, heart disease, hepatic or renal disease and no family history of FH. The ECG showed deep Q wave and inverted T wave in leads II, III and aVF (Fig. 1) and the echocardiogram revealed the diastolic dysfunction of left ventricular with a decreased LV ejection fraction (EF, 48%). The lower extremities ultrasound revealed atherosclerotic plaque in the posterior wall of right common femoral artery. Blood tests showed CK-MB of 21.4 U/L, lactate dehydrogenase of 452 U/L, hs-CRP of 71.2 ng/L, triglyceride (TG) (Triglyceride Kit method) of 0.88 mmol/L, total cholesterol (TC) of 6.87 mmol/L (Cholesterol Kitmethod), low density lipoprotein cholesterol (LDL-C) of 5.90 mmol/L and high density lipoprotein cholesterol (HDL-C) of 1.09 mmol/L (Direct Method-Surfactant Clearance Method).Further laboratory tests revealed highly elevated anticardiolipin antibody (ELISA method) of more than 120RU/ml (0-12RU/ml) and no other abnormal auto-antibodies, including β2-glicoprotein antibodies IgM, IgA, IgG, lupus anticoagulant (LA). DNA analysis for antiphospholipid antibody syndrome (APS) was not performed. Coronary artery angiography (CAG) demonstrated predominant right coronary artery (RCA) and diffuse lesions in the middle and distal segments of the left anterior descending (LAD) artery with the stenosis up to 40~50% (Fig. 2a) and total occlusive RCA from the middle segment (Fig. 2b) with LAD-RCA collateral circulation. With the treatments of anticoagulation (heparin), double antiplatelets (aspirin and ticagrelor) and lipid-modulating (rosuvastatin), he was implanted a stent at the middle segment of the RCA (Fig. 2c). Four days later, he was discharged without any complication. The ECG at discharge showed that the inverted T waves were deeper than those at admission in leads II, III and aVF (Fig. 3). At 6-month follow-up, the laboratory test showed the level of anticardiolipin antibody (ELISA method) was less than 2.0 RU/ml (0-12RU/ml). Lipid profile revealed TG of 0.98 mmol/L, TC of 6.22 mmol/L, LDL-C of 5.53 mmol/L and HDL-C of 0.99 mmol/L.CAG showed 70% in-stent restenosis of the RCA. ECG revealed deep Q waves and inverted T waves (Fig. 4). The patient looked good without any activity restriction and discomfort. At 8-month follow-up, the level of anticardiolipin antibody is less than 2.0 RU/ml and the lipid profile showed TG 0.64 mmol/L, TC 4.15 mmol/L, LDL-C 3.47 mmol/L and HDL-C 1.01 mmol/L.
Fig. 1

Electrocardiogram at admission

Fig. 2

Coronary artery angiography and percutaneous coronary intervention (PCI). a. Left anterior descending artery (LAD); b. Right coronary artery (RCA); c. Implantation of stent in the middle right coronary artery

Fig. 3

Electrocardiogram at discharge

Fig. 4

Electrocardiogram at 6-month follow-up

Electrocardiogram at admission Coronary artery angiography and percutaneous coronary intervention (PCI). a. Left anterior descending artery (LAD); b. Right coronary artery (RCA); c. Implantation of stent in the middle right coronary artery Electrocardiogram at discharge Electrocardiogram at 6-month follow-up

Discussion and conclusions

FH is a risk factor for premature ASCVD [16, 17] and antiphospholipid antibody is a contributor of thrombosis for myocardial infarction [14, 18]. According to the Dutch Lipid Clinic Network (DLCN) Diagnostic criteria (DLCN) [19], the patient was confirmed as possible FH with 5 scores including the premature coronary heart disease (2 points) and LDL-C level of 5.90 mmol/L (3 points). With the International Consensus Statement for Definite APS [20], we could not give a definite diagnosis of APS for this patient. However, the antiphospholipid antibodies can be present in the common population with bacterial or viral infection including HIV, HBV, HCV, herpes virus and parvovirus B19 [15, 21]. Infection-related antibodies will totally disappear once the infection is gone [22]. Although this patient did not have an obvious infectious manifestation before his admission, some occult infections could not be completely excluded. Therefore, transient elevation of anticardiolipin antibody could be a trigger or biomarker for MI in patients with FH [14, 18]; however, the causative effects of transient increased anticardiolipin antibody and MI still need further study.

Limitations

We did not perform the genetic testing about the APS and the test of anticardiolipin antibody at 12-week follow-up.
  22 in total

1.  Familial hypercholesterolaemia: A global call to arms.

Authors:  Antonio J Vallejo-Vaz; Sreenivasa Rao Kondapally Seshasai; Della Cole; G Kees Hovingh; John J P Kastelein; Pedro Mata; Frederick J Raal; Raul D Santos; Handrean Soran; Gerald F Watts; Marianne Abifadel; Carlos A Aguilar-Salinas; Asif Akram; Fahad Alnouri; Rodrigo Alonso; Khalid Al-Rasadi; Maciej Banach; Martin P Bogsrud; Mafalda Bourbon; Eric Bruckert; Josip Car; Pablo Corral; Olivier Descamps; Hans Dieplinger; Ronen Durst; Tomas Freiberger; Isabel M Gaspar; Jaques Genest; Mariko Harada-Shiba; Lixin Jiang; Meral Kayikcioglu; Carolyn S P Lam; Gustavs Latkovskis; Ulrich Laufs; Evangelos Liberopoulos; Lennart Nilsson; Børge G Nordestgaard; John M O'Donoghue; Amirhossein Sahebkar; Heribert Schunkert; Abdulla Shehab; Mario Stoll; Ta-Chen Su; Andrey Susekov; Elisabeth Widén; Alberico L Catapano; Kausik K Ray
Journal:  Atherosclerosis       Date:  2015-09-18       Impact factor: 5.162

2.  Clinical features, management and in-hospital outcome of ST elevation myocardial infarction (STEMI) in young adults under 40 years of age.

Authors:  Seyed Kianoosh Hosseini; Abbas Soleimani; Abbas Ali Karimi; Saeed Sadeghian; Sirous Darabian; Seyed Hesameddin Abbasi; Seyed Hossein Ahmadi; Arezou Zoroufian; Mehran Mahmoodian; Ali Abbasi
Journal:  Monaldi Arch Chest Dis       Date:  2009-06

3.  Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study.

Authors:  Amelia Ruffatti; Teresa Del Ross; Manuela Ciprian; Maria T Bertero; Savino Sciascia; Sciascia Salvatore; Salvatore Scarpato; Carlomaurizio Montecucco; Silvia Rossi; Paola Caramaschi; Domenico Biasi; Andrea Doria; Mariaelisa Rampudda; Nuzzo Monica; Fabio Fischetti; Ugo Picillo; Antonio Brucato; Elisa Salvan; Pengo Vittorio; Pierluigi Meroni; Angela Tincani
Journal:  Ann Rheum Dis       Date:  2011-02-01       Impact factor: 19.103

4.  Knowledge of cardiovascular risk factors and awareness of non-pharmacological approach for risk prevention in young survivors of acute myocardial infarction. The cardiovascular risk prevention project "Help Your Heart Stay Young".

Authors:  Paola Migliaresi; Aldo Celentano; Vittorio Palmieri; Salvatore Pezzullo; Stefania Martino; Manuela Bonito; Bruno Guillaro; Ciro Brancati; Giovanni Di Minno
Journal:  Nutr Metab Cardiovasc Dis       Date:  2007-03-26       Impact factor: 4.222

5.  Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study.

Authors:  Maurizio Turiel; Piercarlo Sarzi-Puttini; Rossana Peretti; Edoardo Rossi; Fabiola Atzeni; Wendy Parsons; Andrea Doria
Journal:  Stroke       Date:  2005-06-09       Impact factor: 7.914

6.  Memory B cells producing somatically mutated antiphospholipid antibodies are present in healthy individuals.

Authors:  Patricia Lieby; Anne Soley; Anne-Marie Knapp; Martine Cerutti; Jean-Marie Freyssinet; Jean-Louis Pasquali; Thierry Martin
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

7.  Identification of familial hypercholesterolemia in patients with myocardial infarction: A Chinese cohort study.

Authors:  Sha Li; Yan Zhang; Cheng-Gang Zhu; Yuan-Lin Guo; Na-Qiong Wu; Ying Gao; Ping Qing; Xiao-Lin Li; Jing Sun; Geng Liu; Qian Dong; Rui-Xia Xu; Chuan-Jue Cui; Jian-Jun Li
Journal:  J Clin Lipidol       Date:  2016-09-02       Impact factor: 4.766

8.  Acute coronary syndrome in patients younger than 30 years--aetiologies, baseline characteristics and long-term clinical outcome.

Authors:  Serban Puricel; Cedric Lehner; Markus Oberhänsli; Tobias Rutz; Mario Togni; Mathieu Stadelmann; Aris Moschovitis; Bernhard Meier; Peter Wenaweser; Stephan Windecker; Jean-Christophe Stauffer; Stéphane Cook
Journal:  Swiss Med Wkly       Date:  2013-07-29       Impact factor: 2.193

9.  Antiphospholipid syndrome.

Authors:  Karen Schreiber; Savino Sciascia; Philip G de Groot; Katrien Devreese; Soren Jacobsen; Guillermo Ruiz-Irastorza; Jane E Salmon; Yehuda Shoenfeld; Ora Shovman; Beverley J Hunt
Journal:  Nat Rev Dis Primers       Date:  2018-01-25       Impact factor: 52.329

10.  Analysis of risk factors, presentation, and in-hospital events of very young patients presenting with ST-elevation myocardial infarction.

Authors:  Edward L Callachan; Alawi A Alsheikh-Ali; Lee A Wallis
Journal:  J Saudi Heart Assoc       Date:  2017-02-05
View more
  1 in total

1.  The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do.

Authors:  Pengfei Wang; Haixia Qiao; RuiJuan Wang; Ruitian Hou; Jingtao Guo
Journal:  BMC Cardiovasc Disord       Date:  2020-12-04       Impact factor: 2.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.